Adjunctive therapies in Kawasaki disease.
Despite the administration of intravenous immunoglobulin (IVIg) at a dose of 2 g/kg, approximately 3-5% of children with acute Kawasaki disease (KD) may develop coronary artery aneurysms. IVIg-resistance, defined as recrudescence of fever more than 36 h after IVIg completion, is a risk factor for coronary artery abnormalities. Thus, several adjunctive therapies are being evaluated for use in IVIg-resistant KD patients and in patients with coronary artery abnormalities. In this review the role of some of these adjunctive therapies in treatment of children with KD is discussed.
['Tremoulet|Adriana H|AH|']
D000276:Adjuvants, Immunologic D004351:Drug Resistance D006801:Humans D016756:Immunoglobulins, Intravenous D007155:Immunologic Factors D009080:Mucocutaneous Lymph Node Syndrome D016896:Treatment Outcome
anakinra atorvastatin cyclosporine etanercept infliximab methylprednisilone